OABI (OmniAb) Total Equity: $262.65 Mil (As of Mar. 2026)


OABI OmniAb Inc OABI
71 GF Score
Price $2.42
GF Value $2.27
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is OmniAb Total Equity?

OmniAb OABI +1.47% 71 Total Equity is $262.65 Mil as of Mar. 2026. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review.

OmniAb's total equity for the quarter that ended in Mar. 2026 was $262.65 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

OmniAb Total Equity Historical Data

* Premium members only.

The historical data trend for OmniAb's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OmniAb Total Equity Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 234.31 341.37 314.59 287.62 267.03

OmniAb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.52 262.06 277.44 267.03 262.65
OABI
71GF Score
OmniAb Inc OABI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OmniAb Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

OmniAb's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=300.914-33.887
=267.03

OmniAb's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=293.65-31.004
=262.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $262.65 Mil mean?
OmniAb (OABI) has a Total Equity of $262.65 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for OmniAb and its competitors.
Is OmniAb's Total Equity too high?
OmniAb's current Total Equity is $262.65 Mil. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Total Equity compare to VNDA and AVIR?
OmniAb's Total Equity of $262.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for OmniAb and its competitors. OmniAb's current Total Equity is $262.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current Total Equity is $262.65 Mil. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For OmniAb (OABI), the current Total Equity is $262.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OmniAb (OABI) Overvalued in 2026?

Based on GuruFocus' analysis, OmniAb stock appears to be overvalued. The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27. GuruFocus considers OmniAb to be Fairly Valued.

Key valuation signals for OABI:

  • Total Equity: $262.65 Mil
  • GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OmniAb Business Description

Address 5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
71GF Score

Get the complete analysis for OABI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.42
Price
$2.27
GF Value